Hepatitis B Treatment Industry - Regional Synopsis
Asia Pacific industry is expected to account for largest revenue share by 2037.
Among the market in these regions, the Asia Pacific market is projected to hold the largest market share by the end of 2029 owing to the increasing prevalence of the viral disease in nations, such as China, Mongolia, Korea, Vietnam, and others, along with the growing need of the nations to find a cure for the viral disease. Alternatively, the hepatitis B treatment market in North America is projected to grow with the highest CAGR during the forecast period owing to the presence of several key players in the region who are increasingly focusing on developing novel therapies and drugs for the treatment of hepatitis B.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of hepatitis B treatment is evaluated at USD 96.07 billion.
Hepatitis B Treatment Market size was valued at USD 92.61 billion in 2024 and is expected to reach USD 162.09 billion by 2037, expanding at around 4.4% CAGR during the forecast period i.e., between 2025-2037.
Asia Pacific industry is expected to account for largest revenue share by 2037, owing to increasing prevalence of the viral disease in nations, such as China, Mongolia, Korea, Vietnam, and others.
The major players in the market are GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi-aventis Groupe, F. Hoffmann-La Roche Ltd., India Immunologicals Ltd., Merck & Co., Inc., Novartis AG, and others.
